HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Targeted therapies continue to improve outcomes in HER-2–positive breast cancer
-
- AMA launches $10 million initiative to remodel medical education
- Experts evaluate relevance of disputed data on HT, breast cancer
- MD Anderson names provost, executive VP
- Mechanical bowel preparation before colon resection reduced mortality, cancer recurrence
- Parents’ attitudes may influence how children’s pain managed at home
- Regimen may help avoid radiotherapy in primary mediastinal B-cell lymphoma
- Report outlines ‘vast variations’ in hospital costs
- Society installs new president
-
- FDA approved Kcentra for urgent reversal of anticoagulation
- FDA approves Tarceva for first-line treatment in patients with NSCLC
- FDA: Confusion between names of breast cancer drugs may cause medication errors
- Genetic link to bladder cancer risk, mortality observed
- Colorectal cancer screening linked to reduced late-stage disease
- MEK inhibitor shows activity in NRAS-mutated melanoma
- Medicare spending disparities failed to affect cancer outcomes
- Missouri consumers misled about cancer risk from indoor tanning
-
- Capecitabine shows promise in pancreatic cancer
- Cetuximab improved survival, response in KRAS wild-type colorectal liver metastases
- Familial risk of cancer not limited to early onset in parents
- Role identified for early palliative care among patients with NSCLC
- ABO blood type increased risk for VTE
- Absolute lymphocyte counts linked to favorable response in childhood ALL
- ACP: Shared decision-making approach urged before PSA testing
- Addition of erlotinib to cisplatin did not increase response, PFS in SCCHN
-
- Autoimmune pancreatitis linked to higher risk for various cancers
- Barasertib improved survival in AML
- Bevacizumab may decrease quality of life in women with ovarian cancer
- Cord blood transplant may be effective in Hurler’s syndrome
- Early HPV vaccination significantly reduced condylomata incidence
- Exemestane, anastrozole conferred similar outcomes in breast cancer
- Exogenous insulin increased risk for complications, mortality in type 2 diabetes
- H. pylori did not increase all-cause mortality risk
-
- Medication errors common in outpatient pediatric cancer care
- No differences observed between Factor VIII products in hemophilia
- Oral SCC patients with close margins may not need adjuvant therapy
- Racial, socioeconomic factors predicted outcomes in ovarian cancer
- Radiation elevated tricuspid regurgitant jet velocity in childhood cancer survivors
- Selective estrogen receptor modulators reduced breast cancer risk up to 5 years
- Vandetanib improved weight in patients with medullary thyroid cancer
- Parenteral estrogen may reduce hormone agonist toxicity in prostate cancer
-
- Death rates, age at diagnoses lower among younger generations in polyposis registry
- Few DLBCL relapses detected solely by post-treatment surveillance scans
- Geography, insurance, hospital type impacted use of laparoscopic surgery for colorectal cancer
- HPV-related diseases perceived as separate concerns by teenage boys
- Ipilimumab plus nivolumab induced long-lasting tumor shrinkage in advanced melanoma
- Laparoscopic, robotic rectal surgery led to faster recovery, similar outcomes to open procedures
- Postsurgical surveillance sufficient for men with stage I seminoma
- Primary tumor resection as initial synchronous colorectal liver metastases therapy increased progression risk
-
- Standard-dose radiation superior to high dose in stage III NSCLC
- Surveillance colonoscopy after colorectal cancer resection may be safely delayed
- Ponatinib: Another new treatment for CML Lisa K. Lohr, PharmD, BCPS, BCOP